Search Results

Rosatom launches project to bring medical students to closed nuclear cities

Rosatom and the Russian Student Teams (RSO) will launch a new medical project in Russia's closed nuclear cities starting in 2027, attracting medical students to work there. Mikhail Kiselev, Chairman of the RSO Supervisory Board and State Duma deputy, announced this to reporters at an event at the Siberian Chemical Combine. Kiselev stated: Starting next year, we plan to launch a large-scale medical project in nuclear cities together with Rosatom, the Russian Student Teams, the Federal Medical-Biological Agency, the Russian Youth Affairs Agency, and the Russian Ministry of Health. This will help systematically attract medical students...

2026-08-11

ITM Receives Complete Response Letter from FDA for ¹⁷⁷Lu-edotreotide New Drug Application

Radiopharmaceutical biotechnology company ITM Isotope Technologies Munich SE (ITM) announced on August 10 that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on August 7, 2026, regarding the New Drug Application (NDA) for its investigational drug ¹⁷⁷Lu-edotreotide (ITM-11). The drug is intended for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

2026-08-11

Russian Ambassador Says Willing to Transfer Civilian Nuclear Technology to Morocco, Covering Power Generation, Seawater Desalination, Nuclear Medicine, and Agriculture

New directions are emerging in Morocco-Russia economic and technical cooperation, with both sides intending to expand the scope of collaboration from traditional energy sectors to strategic industries such as civilian nuclear technology, seawater desalination, medicine, and agriculture. Russia's Ambassador to Morocco, Igor Belyaev, stated that Russia is willing to share civilian nuclear technology expertise with Morocco, a remark indicating that bilateral cooperation may extend from equipment supply and energy projects to more technology-intensive comprehensive partnerships. This development is closely linked to Morocco's current needs. In recent years, Morocco has continuously promoted the diversification of energy sources and accelerated efforts to address water scarcity, with seawater desalination having become a...

2026-08-10

Former U.S. President Biden's Prostate Cancer Progress: Has Received Radiation Therapy and Hormone Therapy

The health condition of former U.S. President Joe Biden has recently drawn renewed attention. In an interview video, his son Hunter Biden stated that after Biden was diagnosed with prostate cancer, the cancer cells had metastasized, spreading to the bones and other parts of the body, and described the process as extremely painful. According to relevant information, Biden, now 83 years old, disclosed in May 2025 that he had been diagnosed with an aggressive form of prostate cancer, with cancer cells confirmed to have spread to the bones at that time. In October, a Biden spokesperson announced that he was undergoing radiation therapy and hormone therapy. Radiation therapy is one of the common nuclear technology medical applications in tumor treatment, primarily using ionizing radiation on tumor tissue to...

2026-08-10

Yongin Severance Hospital in Korea to Review Introduction of Heavy Ion Therapy System

Yonsei University Yongin Severance Hospital is currently reviewing the introduction of a heavy ion therapy system to further strengthen its advanced cancer treatment capabilities. Heavy ion therapy is an advanced radiation therapy technique that typically delivers high-energy precisely to cancer cells by accelerating heavy ions such as carbon ions. This technology leverages the Bragg peak characteristics to concentrate radiation energy release at the tumor site, thereby minimizing exposure to surrounding normal tissues. According to relevant materials, heavy ion therapy is considered to offer new treatment options for certain refractory cancers with limited response to conventional radiotherapy, as well as tumors with high radioresistance. Yongin Severance Hospital hopes to leverage this technology to further...

2026-08-10

Grand Pharma's FAP-targeted diagnostic radiopharmaceutical GPN01530-2 receives FDA Fast Track designation

On August 9, 2026, Grand Pharmaceutical issued a voluntary announcement stating that its self-developed global innovative radionuclide drug conjugate GPN01530-2 has recently been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of solid tumors. Previously, the product had already been approved by the FDA to conduct Phase I/II clinical studies for the diagnosis of solid tumors. GPN01530-2 is a small-molecule radionuclide drug conjugate (RDC) targeting fibroblast activation protein (FAP). Data shows that FAP is not expressed or is lowly expressed in normal tissues, but is highly expressed in tumor-associated fibroblasts within the tumor microenvironment of various cancers, and is considered a novel specific target in the field of tumor diagnosis and treatment...

2026-08-10

South Korea to Resume Actinium-225 Production Next Year to Ease Shortage of Raw Materials for Anti-Cancer Radiopharmaceuticals

South Korea's domestic production project for actinium-225 (Ac-225), a radioisotope used in next-generation cancer treatment, is expected to resume next year after being stalled for more than a year. Funding was secured in the first half of this year, and the Korea Institute of Radiological & Medical Sciences (KIRAMS) plans to complete facility construction and trial production before launching full-scale production in the second half of next year, aiming to alleviate the raw material shortage facing domestic clinical research and radiopharmaceutical development. KIRAMS is affiliated with the Ministry of Science and ICT. The institute received approval from the Nuclear Safety and Security Commission in May last year to produce Ac-225 using a cyclotron. The project first entered the review process in 2018 and took seven years to gain approval, with initial production originally planned by the end of last year. However, work on upgrading production facilities and procuring equipment was suspended after approximately 2 billion KRW in budget was not approved during parliamentary review.

2026-08-10

Fractionated radiotherapy did not significantly alter surface properties of two types of dental restorative composites

On August 5, a recently published in vitro study showed that under a simulated clinical head and neck cancer radiotherapy regimen, the surface microhardness and roughness of two modern dental restorative composites did not change significantly. The study focused on the effects of therapeutic ionizing radiation on the durability of dental restorative materials. After head and neck cancer patients receive radiotherapy, the oral environment may change, including reduced saliva secretion, mucositis, radiation caries, and other issues, which may affect the surface condition and long-term performance of restorations. To this end, the research team selected Giomer resin composite based on glass ionomer technology and Or...

2026-08-10

Japanese research team uses PET imaging to find tau protein pathology may be involved in onset of hallucinations and delusions in middle-aged and elderly

A research team comprising the National Institutes for Quantum Science and Technology (QST), Keio University, Kyoto University, Tokyo University of Science, and other institutions recently announced that researchers used PET imaging to observe tau protein pathology in the living brains of middle-aged and elderly psychiatric patients, and believe that such pathology may be related to psychiatric symptoms such as hallucinations and delusions that first appear after age 40. Proportion of positive tau PET and amyloid PET results Middle-aged and elderly psychosis generally refers to diseases in which psychiatric symptoms such as hallucinations and delusions first appear after age 40. Previous epidemiological studies and postmortem brain tissue studies have suggested that such symptoms may be related to neurodegenerative changes associated with dementia, but due to limited techniques for precise visualization and quantification of abnormal proteins in living brains, relevant evidence has long been insufficient.

2026-08-10

Consolidating Foundations·Sichuan: Accelerated Localization of Nuclear Medical Equipment Benefits the Public

On August 9, 2026, CCTV's "Morning News" program aired a feature titled "Consolidating Foundations·Sichuan: Accelerated Localization of Nuclear Medical Equipment Benefits the Public," reporting on Jiuyiyuan Company. Founded in February 2017, Sichuan Jiuyiyuan Particle Technology Co., Ltd. is a national high-tech enterprise integrating R&D, production, and services of high-end nuclear medical equipment, committed to providing overall solutions for radiopharmaceuticals. A cyclotron is a device that uses magnetic and electric fields to drive charged particles in a circular motion, repeatedly accelerating them via high-frequency electric fields during their movement. Low- and medium-energy cyclotrons applied in the medical field are devices that produce positron-emitting radionuclides, generating a variety of radionuclides that not only meet clinical PET/CT examination needs but also support the clinical positron drug and new drug development demands of the molecular imaging and precision medicine era. The report noted that core nuclear medicine equipment has long relied on imports, which is a key bottleneck constraining the development of nuclear medicine in China. In 2021, Jiuyiyuan successfully developed the first domestically produced medical cyclotron, breaking foreign technological monopoly. In June this year, the company launched the first domestically produced 30MeV multi-particle medium-to-high-energy cyclotron with fully independent intellectual property rights, with mass production planned for September, achieving internationally advanced product performance.

2026-08-10

UAB startup LifeNuclear launches TheraGuide, a radiation safety guidance platform for radiopharmaceutical therapy

On August 7, LifeNuclear, a medical technology startup incubated by the University of Alabama at Birmingham (UAB), announced the launch of TheraGuide, a digital platform designed to help patients undergoing radiopharmaceutical cancer treatment understand and follow radiation safety guidance after discharge. Radiopharmaceutical therapy uses radioactive drugs to target cancer cells while minimizing damage to surrounding healthy tissue. As the therapy's applications expand, patients are typically required to read and follow complex written instructions after treatment, which can be difficult for some patients and caregivers to understand and execute. Dr. Remo George LifeNuclear was founded by UAB...

2026-08-08

228 Research Reactors Worldwide in Operation, Supporting Medical Isotope Production and Neutron Science Innovation

According to the International Atomic Energy Agency on August 7, research reactors continue to drive innovation in science, medicine, and industry worldwide. Currently, 228 research reactors are in operation across 54 countries, with another 23 under construction or in the planning stage. Unlike nuclear reactors used for power generation, these reactors primarily produce neutrons to support medical, industrial, agricultural, geological, forensic, and nuclear science research. A research reactor pool photographed from above. (Photo: IAEA) In the medical field, research reactors are a vital source of medical radioisotopes. Among them, technetium-99m is widely used for diagnosing cancer and diseases of the heart, brain, and bones; a large number of medical diagnostic and therapeutic procedures worldwide rely on this isotope. Other radioisotopes such as iodine-131 are also used in the treatment of cancer and thyroid diseases. The IAEA states that radioisotopes produced by research reactors serve millions of patients globally and are an essential component of modern nuclear medicine systems.

2026-08-09

Cancer Cryoablation Treatments at Southeast Region Nuclear Medicine Center in Korea Exceed 100 Cases

The Southeast Region Nuclear Medicine Center announced on August 8 that since introducing cancer cryoablation in 2024, the center has completed over 100 related procedures, providing treatment to a total of 104 cancer patients. Cryoablation is a minimally invasive tumor treatment method. During the procedure, doctors insert a thin treatment needle precisely into the tumor site under CT or ultrasound imaging guidance, freezing the lesion at ultra-low temperatures of minus 40 degrees Celsius or lower to cause cancer cell necrosis. As the low-temperature freezing itself has a certain anesthetic effect, this technique helps reduce patient pain, minimize damage to surrounding normal tissues, and promote faster postoperative recovery. According to the center, among the patients treated so far, there are 58 cases of liver cancer and liver metastases, 17 cases of primary lung cancer, recurrent lung cancer, and lung metastases, and 29 cases of renal cancer. Among them, 8 patients underwent treatment for two lesions simultaneously in a single procedure. Liver...

2026-08-08

CNNC Fuzhi Officially Established, CNNC Isotope Holds 90% Stake to Integrate the Full Nuclear Medicine Industry Chain

On August 6, 2026, CNNC Fuzhi (Beijing) Technology Co., Ltd. (hereinafter referred to as "CNNC Fuzhi") was officially established. The company was jointly funded by CNNC Isotope Co., Ltd. (hereinafter referred to as "CNNC Isotope") and CNNC (Zhejiang) Innovation Co., Ltd. (hereinafter referred to as "CNNC Zhejiang Innovation"), with CNNC Isotope holding 90% of the shares and CNNC Zhejiang Innovation holding 10%. CNNC Fuzhi will take over the business of CNNC Isotope's Nuclear Medicine Development Center, focusing on deep cultivation in the smart nuclear medicine sector. With the smart nuclear medicine IoT system as its core carrier, the company aims to integrate the entire nuclear medicine industry chain, build a synergistic development model of "smart nuclear medicine system + nuclear drugs + equipment + services," and drive the business transition from single product supply to full value chain integration...

2026-08-08

Institute of Radiation Medicine, Chinese Academy of Medical Sciences Hosts Academic Seminar on PSMA-Targeted Radiopharmaceuticals

On August 3, the Institute of Radiation Medicine, Chinese Academy of Medical Sciences held an academic seminar, inviting Professor Lin Guoxian from the BC Cancer Agency in Vancouver, Canada, to deliver a lecture titled "Development of Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals for the Diagnosis and Treatment of Prostate Cancer." The seminar was held in a hybrid format, with some researchers and graduate students from the institute attending in person. Professor Lin Guoxian has long been engaged in the development of targeted radiopharmaceuticals for cancer diagnosis and therapy, having led or contributed to the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed clinical translation of 7 self-developed radiopharmaceuticals applied in...

2026-08-07